Bringing Decades of Value-Based Care Insights & Innovation
Fernandina Beach, FL – February 4th, 2025 – GalenusRx, a leader in precision medication safety, is pleased to announce the appointment of Jason Feuerman to its advisory board. Mr. Feuerman brings a wealth of experience in healthcare innovation and strategic leadership to the team.
With a distinguished career spanning over three decades in healthcare, Jason Feuerman has been at the forefront of healthcare advancements, driving significant improvements in patient outcomes and operational efficiencies. His expertise in integrating cutting-edge technologies with healthcare practices aligns perfectly with GalenusRx’s mission to revolutionize medication safety through precision and personalized care. His most recent role as CEO of LTC ACO, the first ACO in the US dedicated solely to facility-based residents, which announced its savings in the Medicare Shared Savings Program for 2023 of $60 MM, makes him one of a few pioneers in value-based care. Prior to that, he had been President of Bravo Health, a PA and MD based Medicare Advantage Plan for 16 years.
“We are thrilled to welcome Jason Feuerman to our advisory board,” said Calvin H. Knowlton, PhD, Co-CEO and Executive Chairman, GalenusRx. “His insights and experience will be invaluable as we continue to expand our innovative solutions and enhance the safety and efficacy of medication regimens for patients worldwide.”
Mr. Feuerman expressed his enthusiasm about joining GalenusRx, stating, “I am excited to be part of a team that is dedicated to making a real difference in medication safety. GalenusRx’s commitment to leveraging advanced scientific knowledge and personalized assessments is truly groundbreaking, and I look forward to contributing to their mission.”
Contact: GalenusRx Communications Team Email: [email protected] Phone: (855) 425-3687.
